The American Society of Hematology (ASH) released guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and ...

Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American ...

The American Society of Hematology (ASH) released guidelines on the diagnosis of light chain (AL) amyloidosis, a rare and life-threatening disease of ...

Driven by accelerating diagnosis of ATTR cardiomyopathy, sustained reliance on cost-effective chemotherapy, and rapid uptake ...

Jan. 26, 2004 — High-dose melphalan with autologous stem-cell transplant improves five-year survival, induces remission, or reverses disease in a substantial proportion of patients with AL amyloidosis ...

Prof. Liu Cong from the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences, along with collaborators, has revealed the high-resolution structures of amyloid fibrils directly ...

Birtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints Birtamimab development will be discontinued, including stopping the open label extension of the ...

ZURICH, Dec. 4, 2025 /PRNewswire/ -- Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease by ...

LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL ...

Systemic light chain (AL) amyloidosis is a rare and life-threatening disorder characterized by the deposition of misfolded immunoglobulin light chains as insoluble amyloid fibrils in various tissues ...

AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain depleter antibody, anselamimab, in certain patients with a rare disease called ...

Prothena Corporation plc (NASDAQ:PRTA) released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday. AL (amyloid light-chain) amyloidosis is ...